RenovoRx, Inc. (RNXT)
RNXT Stock Price Chart
Explore RenovoRx, Inc. interactive price chart. Choose custom timeframes to analyze RNXT price movements and trends.
RNXT Company Profile
Discover essential business fundamentals and corporate details for RenovoRx, Inc. (RNXT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Aug 2021
Employees
10.00
Website
https://renovorx.comCEO
Shaun R. Bagai
Description
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RNXT Financial Timeline
Browse a chronological timeline of RenovoRx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.08, while revenue estimate is $703.75k.
Earnings released on 14 May 2026
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $563.00k , beating expectations by +19.91%.
Earnings released on 30 Mar 2026
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $238.00k , missing expectations by -43.29%.
Earnings released on 13 Nov 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $266.00k , missing expectations by -34.39%.
Earnings released on 14 Aug 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $422.00k , beating expectations by +38.82%.
Earnings released on 15 May 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $197.00k , beating expectations by +7.46%.
Earnings released on 31 Mar 2025
EPS came in at -$0.12 surpassing the estimated -$0.13 by +7.69%, while revenue for the quarter reached $43.00k , missing expectations by -74.33%.
Earnings released on 13 Nov 2024
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%.
Earnings released on 13 Aug 2024
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 10 May 2024
EPS came in at -$0.07 surpassing the estimated -$0.14 by +50.00%.
Earnings released on 1 Apr 2024
EPS came in at -$0.17 surpassing the estimated -$0.30 by +43.33%.
Earnings released on 13 Nov 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.
Earnings released on 16 Aug 2023
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%.
Earnings released on 15 May 2023
EPS came in at -$0.36 falling short of the estimated -$0.25 by -44.00%.
Earnings released on 2 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%.
Earnings released on 14 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%.
Earnings released on 15 Aug 2022
EPS came in at -$0.29 falling short of the estimated -$0.26 by -11.54%.
Earnings released on 16 May 2022
EPS came in at -$0.33 falling short of the estimated -$0.25 by -32.00%.
Earnings released on 30 Mar 2022
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%.
Earnings released on 15 Nov 2021
EPS came in at -$0.27 falling short of the estimated -$0.21 by -28.57%.
Earnings released on 27 Aug 2021
EPS came in at -$0.08 .
RNXT Stock Performance
Access detailed RNXT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
